129 related articles for article (PubMed ID: 10718779)
21. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
22. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
Arch Toxicol; 2013 Dec; 87(12):2129-39. PubMed ID: 24221535
[TBL] [Abstract][Full Text] [Related]
23. Dietary effects of Sideritis scardica "mountain tea" on human in vivo activities of xenobiotic metabolizing enzymes in healthy subjects.
Begas E; Kilindris T; Kouvaras E; Tsioutsioumi A; Kouretas D; Asprodini EK
Food Chem Toxicol; 2018 Dec; 122():38-48. PubMed ID: 30266316
[TBL] [Abstract][Full Text] [Related]
24. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities.
McQuilkin SH; Nierenberg DW; Bresnick E
Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):139-46. PubMed ID: 7742721
[TBL] [Abstract][Full Text] [Related]
25. Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity.
Cribb AE; Isbrucker R; Levatte T; Tsui B; Gillespie CT; Renton KW
Pharmacogenetics; 1994 Jun; 4(3):166-70. PubMed ID: 7920698
[TBL] [Abstract][Full Text] [Related]
26. N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians.
Aklillu E; Carrillo JA; Makonnen E; Bertilsson L; Djordjevic N
Eur J Clin Pharmacol; 2018 Jul; 74(7):903-911. PubMed ID: 29589062
[TBL] [Abstract][Full Text] [Related]
27. Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug.
Vrtic F; Haefeli WE; Drewe J; Krähenbühl S; Wenk M
Br J Clin Pharmacol; 2003 Feb; 55(2):191-8. PubMed ID: 12580991
[TBL] [Abstract][Full Text] [Related]
28. Re-investigation of the concordance of human NAT2 phenotypes and genotypes.
Bolt HM; Selinski S; Dannappel D; Blaszkewicz M; Golka K
Arch Toxicol; 2005 Apr; 79(4):196-200. PubMed ID: 15558239
[TBL] [Abstract][Full Text] [Related]
29. Caffeine, selected metabolic gene variants, and risk for neural tube defects.
Schmidt RJ; Romitti PA; Burns TL; Murray JC; Browne ML; Druschel CM; Olney RS;
Birth Defects Res A Clin Mol Teratol; 2010 Jul; 88(7):560-9. PubMed ID: 20641098
[TBL] [Abstract][Full Text] [Related]
30. Urinary mutagenicity, CYP1A2 and NAT2 activity in textile industry workers.
Fanlo A; Sinuès B; Mayayo E; Bernal L; Soriano A; Martínez-Jarreta B; Martínez-Ballarín E
J Occup Health; 2004 Nov; 46(6):440-7. PubMed ID: 15613766
[TBL] [Abstract][Full Text] [Related]
31. Coffee and tea consumption, genotype-based CYP1A2 and NAT2 activity and colorectal cancer risk-results from the EPIC cohort study.
Dik VK; Bueno-de-Mesquita HB; Van Oijen MG; Siersema PD; Uiterwaal CS; Van Gils CH; Van Duijnhoven FJ; Cauchi S; Yengo L; Froguel P; Overvad K; Bech BH; Tjønneland A; Olsen A; Boutron-Ruault MC; Racine A; Fagherazzi G; Kühn T; Campa D; Boeing H; Aleksandrova K; Trichopoulou A; Peppa E; Oikonomou E; Palli D; Grioni S; Vineis P; Tumino R; Panico S; Peeters PH; Weiderpass E; Engeset D; Braaten T; Dorronsoro M; Chirlaque MD; Sánchez MJ; Barricarte A; Zamora-Ros R; Argüelles M; Jirström K; Wallström P; Nilsson LM; Ljuslinder I; Travis RC; Khaw KT; Wareham N; Freisling H; Licaj I; Jenab M; Gunter MJ; Murphy N; Romaguera-Bosch D; Riboli E
Int J Cancer; 2014 Jul; 135(2):401-12. PubMed ID: 24318358
[TBL] [Abstract][Full Text] [Related]
32. Concordance between the deduced acetylation status generated by high-speed: real-time PCR based NAT2 genotyping of seven single nucleotide polymorphisms and human NAT2 phenotypes determined by a caffeine assay.
Rihs HP; John A; Scherenberg M; Seidel A; Brüning T
Clin Chim Acta; 2007 Feb; 376(1-2):240-3. PubMed ID: 17011540
[TBL] [Abstract][Full Text] [Related]
33. A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test.
Saruwatari J; Nakagawa K; Shindo J; Tajiri T; Fujieda M; Yamazaki H; Kamataki T; Ishizaki T
Clin Pharmacol Ther; 2002 Aug; 72(2):200-8. PubMed ID: 12189367
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis.
Wadelius M; Stjernberg E; Wiholm BE; Rane A
Pharmacogenetics; 2000 Feb; 10(1):35-41. PubMed ID: 10739170
[TBL] [Abstract][Full Text] [Related]
35. Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers.
Chen Y; Xiao P; Ou-Yang DS; Fan L; Guo D; Wang YN; Han Y; Tu JH; Zhou G; Huang YF; Zhou HH
Clin Exp Pharmacol Physiol; 2009 Aug; 36(8):828-33. PubMed ID: 19215233
[TBL] [Abstract][Full Text] [Related]
36. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2.
Han XM; Ou-Yang DS; Lu PX; Jiang CH; Shu Y; Chen XP; Tan ZR; Zhou HH
Pharmacogenetics; 2001 Jul; 11(5):429-35. PubMed ID: 11470995
[TBL] [Abstract][Full Text] [Related]
37. Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians.
Welfare MR; Aitkin M; Bassendine MF; Daly AK
Pharmacogenetics; 1999 Jun; 9(3):367-75. PubMed ID: 10471069
[TBL] [Abstract][Full Text] [Related]
38. Influence of the urine flow rate on some caffeine metabolite ratios used to assess CYP1A2 activity.
Sinués B; Fanlo A; Bernal ML; Mayayo E; Soriano MA; Martínez-Ballarin E
Ther Drug Monit; 2002 Dec; 24(6):715-21. PubMed ID: 12451287
[TBL] [Abstract][Full Text] [Related]
39. Heritability of Caffeine Metabolism: Environmental Effects Masking Genetic Effects on CYP1A2 Activity but Not on NAT2.
Matthaei J; Tzvetkov MV; Strube J; Sehrt D; Sachse-Seeboth C; Hjelmborg JB; Möller S; Halekoh U; Hofmann U; Schwab M; Kerb R; Brockmöller J
Clin Pharmacol Ther; 2016 Dec; 100(6):606-616. PubMed ID: 27509179
[TBL] [Abstract][Full Text] [Related]
40. Correlation between assessment of cytochrome P450 1A2 activity and enzyme activity scores, and their relation to clozapine exposure.
Alarcan H; Cannet P; Camus V; Fond G; Zendjidjian X; Guilhaumou R; Quaranta S
Br J Clin Pharmacol; 2023 May; 89(5):1665-1671. PubMed ID: 36507652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
